Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2013 Jan 13;71(4):883–892. doi: 10.1007/s00280-013-2079-z

Table 2.

Adverse events, regardless of their relationship to the study drug.

Adverse Event All Grades % Grade 3–4 %
Fatigue 16 51.6%
LFT elevations 15 48.4% 2 6.5%
Nausea 12 38.7%
Anorexia 8 25.8%
Constipation 6 19.4%
Diarrhea 5 16.1%
Alopecia 4 12.9%
Dehydration 4 12.9% 2 6.5%
Leukopenia 3 9.7% 2 6.5%
Neutropenia 3 9.7% 3 9.7%
Thrombocytopenia 3 9.7% 2 6.5%
Creatinine elevation 3 9.7%
Headache 3 9.7%
Bone pain 3 9.7% 2 6.5%
Anemia 2 6.5% 2 6.5%